BioStem Technologies Announces Up-Listing to the OTCQB Venture Market

Rhea-AI Summary

BioStem Technologies Inc. (OTCQB: BSEM) has successfully up-listed its shares from the OTC Pink Sheet to the OTCQB Venture Market on December 16, 2022. This milestone reflects the company's commitment to transparency and corporate governance, enhancing visibility and accessibility for U.S. investors.

CEO Jason Matuszewski emphasized the significance of this achievement in expanding their shareholder base and providing value to current shareholders. BioStem specializes in placental derived biologics and aims to leverage innovative processing methods to advance regenerative therapies.

Positive

• Successful up-listing to the OTCQB Venture Market enhances company visibility.
• Commitment to transparency and good corporate governance demonstrated.
• Potential to expand the shareholder base and increase accessibility for U.S. investors.

Negative

• None.

POMPANO BEACH, FLORIDA., Dec. 16, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTCQB: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, is pleased to announce that its common shares have been successfully up-listed from the OTC Pink Sheet Open Market to the OTCQB Venture Market (the “OTCQB”) by the OTC Markets Group Inc. (“OTC Markets”). The Company’s common shares will begin trading on the OTCQB under the symbol “BSEM” as of the opening of market on December 16, 2022.

Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, “our up-listing on the OTCQB Venture Market is an important milestone in demonstrating our commitment to transparency and good corporate governance to our shareholders. The OTCQB also provides an opportunity to build our visibility and expand our shareholder base on an established public market. This will ultimately increase accessibility for U.S. Investors and provide additional value to our shareholders.”

About BioStem Technologies, Inc. (OTCQB: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain^® processing method. BioRetain^® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJE^TM, VENDAJE^TM AC, and VENDAJE^TM OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. 

Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStem Technologies

Investor Relations:
Russo Partners, LLC
Nic Johnson and Maxim Jacobs, CFA
12 West 27th Street, 4th Floor
New York, NY 10001
T: 646-942-5591
Nic.Johnson@russopartnersllc.com
Maxim.Jacobs@russopartnersllc.com 

FAQ

What is the significance of BioStem Technologies' up-listing to OTCQB?

The up-listing enhances visibility and accessibility for investors, reflecting the company's commitment to transparency and governance.

When did BioStem Technologies start trading on the OTCQB?

BioStem Technologies began trading on the OTCQB on December 16, 2022.

What does BioStem Technologies focus on?

BioStem Technologies focuses on developing, manufacturing, and commercializing placental derived biologics for regenerative therapies.

What stock symbol is associated with BioStem Technologies on the OTCQB?

BioStem Technologies trades under the symbol 'BSEM' on the OTCQB.